Crosstalk between Methylation and ncRNAs in Breast Cancer: Therapeutic and Diagnostic Implications

Yitong Liu1, Ping Leng1, Yan Liu1

  • 1College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610000, China.

Insights

This review explores the intricate interplay between DNA methylation and non-coding RNAs (ncRNAs) in breast cancer development. Understanding these epigenetic interactions offers new avenues for breast cancer diagnostics and therapies.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Breast cancer is a heterogeneous malignancy with complex etiology.
  • Aberrant epigenetic mechanisms, including DNA methylation and non-coding RNA (ncRNA) dysregulation, are implicated in its development.
  • N6-methyladenosine (m6A) and histone methylation are key epigenetic modifications in breast cancer.

Purpose of the Study:

  • To elaborate on the crosstalk between major methylation modifications and ncRNAs in breast cancer.
  • To discuss the role of these interactions in promoting breast cancer oncogenesis.
  • To provide insights into novel diagnostic markers and therapeutic strategies.

Main Methods:

  • Review of existing literature on epigenetic modifications and ncRNAs in breast cancer.
  • Analysis of the intricate regulatory networks formed by methylation and ncRNAs.
  • Discussion of the functional roles of these interactions in cancer progression.

Main Results:

  • Methylation modifications and ncRNAs engage in complex crosstalk, forming networks that drive breast cancer genesis.
  • Specific interactions between methylation patterns and various ncRNAs (miRNAs, lncRNAs, circRNAs) are crucial for oncogenesis.
  • These interactions play significant roles in the initiation and progression of breast cancer.

Conclusions:

  • The interplay between methylation and ncRNAs is fundamental to breast cancer development.
  • Targeting these epigenetic interactions may lead to novel diagnostic biomarkers based on ncRNA methylation patterns.
  • Combination therapies involving ncRNA oligonucleotides and phytochemicals show promise for breast cancer treatment.